According to Regulus Therapeutics's latest financial reports the company's total debt is $3.36 M. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2022-12-31 | $6.27 M | -11.44% |
2021-12-31 | $7.09 M | 52.41% |
2020-12-31 | $4.65 M | -68.2% |
2019-12-31 | $14.63 M | -11.73% |
2018-12-31 | $16.57 M | -16.54% |
2017-12-31 | $19.85 M | 0.29% |
2016-12-31 | $19.8 M | |
2014-12-31 | $23.39 M | 107.44% |
2013-12-31 | $11.27 M | 11.3% |
2012-12-31 | $10.13 M | 1.34% |
2011-12-31 | $10 M |
Company | Total debt | differencediff. | Country |
---|---|---|---|
Sanofi SNY | $20.36 B | 604,623.87% | ๐ซ๐ท France |
Biogen BIIB | $7.33 B | 217,780.05% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $41.46 B | 1,231,016.39% | ๐บ๐ธ USA |
AstraZeneca AZN | $28.62 B | 849,721.85% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $22.93 B | 680,924.35% | ๐ฌ๐ง UK |
Sangamo Therapeutics
SGMO | $38.1 M | 1,031.35% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | N/A | N/A | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $1.30 B | 38,658.61% | ๐บ๐ธ USA |